{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:08:55Z","timestamp":1793995735313,"version":"4.8.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070871"],"award-info":[{"award-number":["82070871"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Obesity is increasingly becoming a global epidemic of concern and is considered a risk factor for several endocrine-related cancers. Moreover, obesity is associated with cancer development and poor prognosis. As a metabolic abnormality, obesity leads to a series of changes in insulin, IGF-1, sex hormones, IGFBPs, and adipokines. Among these factors, IGF-1 plays an important role in obesity-related endocrine cancers. This review describes the role of obesity in endocrine-related cancers, such as prostate cancer, breast cancer and pancreatic cancer, focusing on the mechanism of IGF-1 and the crosstalk with estrogen and adipokines. In addition, this review briefly introduces the current status of IGF-1R inhibitors in clinical practice and shows the prospect of IGF-1R inhibitors in combination with other anticancer drugs.<\/jats:p>","DOI":"10.3389\/fendo.2023.1093257","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T06:18:57Z","timestamp":1674454737000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":65,"title":["Obesity and endocrine-related cancer: The important role of IGF-1"],"prefix":"10.3389","volume":"14","author":[{"given":"Wentao","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3322\/caac.21499","article-title":"Global patterns in excess body weight and the associated cancer burden","volume":"69","author":"Sung","year":"2019","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2019.01.041","article-title":"How the association between obesity and inflammation may lead to insulin resistance and cancer","volume":"13","author":"Amin","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmu060","article-title":"Obesity and the reproductive system disorders: Epigenetics as a potential bridge","volume":"21","author":"Crujeiras","year":"2015","journal-title":"Hum Reprod Update"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/JME-15-0310","article-title":"Aromatase expression and regulation in breast and endometrial cancer","volume":"57","author":"Zhao","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2359","article-title":"Modifying Igf1 activity: An approach to treat endocrine disorders, atherosclerosis and cancer","volume":"6","author":"Clemmons","year":"2007","journal-title":"Nat Rev Drug Discovery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020555","article-title":"Disrupting insulin and igf receptor function in cancer","volume":"22","author":"Cao","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.5040","article-title":"Small is beautiful: Insulin-like growth factors and their role in growth, development, and cancer","volume":"28","author":"Maki","year":"2010","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080895","article-title":"Therapeutic targeting of the igf axis","volume":"8","author":"Osher","year":"2019","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051261","article-title":"Igfbp-3\/Igfbp-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer","volume":"9","author":"Cai","year":"2020","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/JME-17-0254","article-title":"Igf-binding proteins","volume":"61","author":"Bach","year":"2018","journal-title":"J Mol Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2020.04.005","article-title":"Advances in insulin-like growth factor biology and -directed cancer therapeutics","volume":"147","author":"Fettig","year":"2020","journal-title":"Adv Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.metabol.2018.12.006","article-title":"Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine","volume":"92","author":"Nimptsch","year":"2019","journal-title":"Metabolism"},{"key":"B13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s12885-020-07089-5","article-title":"Does increased body mass index lead to elevated prostate cancer risk? it depends on waist circumference","volume":"20","author":"Choi","year":"2020","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bju.14594","article-title":"Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: Results from the search database","volume":"124","author":"Freedland","year":"2019","journal-title":"BJU Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.09.007","article-title":"Measures of body fatness and height in early and mid-to-Late adulthood and prostate cancer: Risk and mortality in the pooling project of prospective studies of diet and cancer","volume":"31","author":"Genkinger","year":"2020","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2152\/jmi.65.9","article-title":"Adipose Tissue:Critical contributor to the development of prostate cancer","volume":"65","author":"Uehara","year":"2018","journal-title":"J Med Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0880-9","article-title":"Circulating igf-1 promotes prostate adenocarcinoma Via Foxo3a\/Bim signaling in a double-transgenic mouse model","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23389","article-title":"Investigating the role of the igf axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery","volume":"77","author":"Breen","year":"2017","journal-title":"Prostate"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1884","article-title":"Oncogenic functions of Igf1r and insr in prostate cancer include enhanced tumor growth, cell migration and angiogenesis","volume":"5","author":"Heidegger","year":"2014","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076513","article-title":"Igf-ir promotes prostate cancer growth by stabilizing Alpha5beta1 integrin protein levels","volume":"8","author":"Sayeed","year":"2013","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/ERC-21-0107","article-title":"Serum markers, obesity and prostate cancer risk: Results from the prostate cancer prevention trial","volume":"29","author":"Chau","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.11.013","article-title":"Obesity and prostate cancer: Weighing the evidence","volume":"63","author":"Allott","year":"2013","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3082","article-title":"Assessment of expression levels of leptin and leptin receptor as potential biomarkers for risk of prostate cancer development and aggressiveness","volume":"9","author":"Kamel","year":"2020","journal-title":"Cancer Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2019.03.006","article-title":"Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis","volume":"13","author":"Yoon","year":"2019","journal-title":"Obes Res Clin Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2018.0261","article-title":"Role of adiponectin in prostate cancer","volume":"45","author":"Hu","year":"2019","journal-title":"Int Braz J Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111692","article-title":"Peri-prostatic adipocyte-released tgfbeta enhances prostate cancer cell motility by upregulation of connective tissue growth factor","volume":"9","author":"La Civita","year":"2021","journal-title":"Biomedicines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0058","article-title":"Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer","volume":"25","author":"Mangiola","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/bju.14173","article-title":"Peri-prostatic adipose tissue: The metabolic microenvironment of prostate cancer","volume":"121","author":"Nassar","year":"2018","journal-title":"BJU Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2017.31","article-title":"Periprostatic adipose inflammation is associated with high-grade prostate cancer","volume":"20","author":"Gucalp","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1546","article-title":"Overweight, obesity, and postmenopausal invasive breast cancer risk: A secondary analysis of the women's health initiative randomized clinical trials","volume":"1","author":"Neuhouser","year":"2015","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12282-020-01182-0","article-title":"Obesity-related protein biomarkers for predicting breast cancer risk: An overview of systematic reviews","volume":"28","author":"Wu","year":"2021","journal-title":"Breast Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70095-4","article-title":"Insulin-like growth factor 1 (Igf1), igf binding protein 3 (Igfbp3), and breast cancer risk: Pooled individual data analysis of 17 prospective studies","volume":"11","author":"Endogenous","year":"2010","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S308554","article-title":"Analysis of increased egfr and igf-1r signaling and its correlation with socio-epidemiological features and biological profile in breast cancer patients: A study in northern Brazil","volume":"13","author":"Silva Rocha","year":"2021","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1529-8","article-title":"Insulin-like growth factor receptor (Igf-1r) in breast cancer subtypes","volume":"132","author":"Yerushalmi","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B36","doi-asserted-by":"publisher","first-page":"R59","DOI":"10.1186\/bcr3453","article-title":"Obesity enhances nongenomic estrogen receptor crosstalk with the Pi3k\/Akt and mapk pathways to promote in vitro measures of breast cancer progression","volume":"15","author":"Bowers","year":"2013","journal-title":"Breast Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-4626-8","article-title":"Multiple signaling pathways are activated during insulin-like growth factor-I (Igf-I) stimulated breast cancer cell migration","volume":"93","author":"Zhang","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00058","article-title":"Metabolic health, insulin, and breast cancer: Why oncologists should care about insulin","volume":"11","author":"Yee","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.02.089","article-title":"Dynamics of estrogen-induced ros and DNA strand break generation in estrogen receptor alpha-positive breast cancer","volume":"602","author":"Zhang","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188482","article-title":"Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis","volume":"1875","author":"Rajan","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2019.9879","article-title":"Estradiol induces cell proliferation in Mcf7 mammospheres through Her2\/Cox2","volume":"19","author":"Wu","year":"2019","journal-title":"Mol Med Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-4094-3","article-title":"Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: Analysis of paired serum and tumor tissue samples","volume":"162","author":"Kakugawa","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01474","article-title":"Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women","volume":"102","author":"Hetemaki","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/00001648-199601000-00017","article-title":"Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer","volume":"7","author":"Lipworth","year":"1996","journal-title":"Epidemiology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1530\/EJE-16-0834","article-title":"Modulation of shbg binding to testosterone and estradiol by sex and morbid obesity","volume":"176","author":"Grasa","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062642","article-title":"Interaction between igf-ir and er induced by E2 and igf-I","volume":"8","author":"Yu","year":"2013","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12281","article-title":"The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: Potential effects of exercise","volume":"16","author":"Schmidt","year":"2015","journal-title":"Obes Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.12.8562","article-title":"Leptin enhances growth inhibition by camp elevating agents through apoptosis of mda-Mb-231 breast cancer cells","volume":"8","author":"Naviglio","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22288","article-title":"Leptin potentiates antiproliferative action of camp elevation Via protein kinase a down-regulation in breast cancer cells","volume":"225","author":"Naviglio","year":"2010","journal-title":"J Cell Physiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6212","article-title":"Leptin promotes the growth of breast cancer by upregulating the Wnt\/Beta-catenin pathway","volume":"16","author":"Liang","year":"2018","journal-title":"Exp Ther Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2017.4291","article-title":"Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer","volume":"13","author":"Hosney","year":"2017","journal-title":"Exp Ther Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2017.05.058","article-title":"Leptin induces creb-dependent aromatase activation through cox-2 expression in breast cancer cells","volume":"106","author":"Kim","year":"2017","journal-title":"Food Chem Toxicol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2017.273","article-title":"Leptin regulation of the P53-Hif1alpha\/Pkm2-Aromatase axis in breast adipose stromal cells: A novel mechanism for the obesity-breast cancer link","volume":"42","author":"Zahid","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1129","article-title":"Estradiol affects extracellular Leptin:Adiponectin ratio in human breast tissue in vivo","volume":"99","author":"Morad","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701315R","article-title":"Uncoupling effects of estrogen receptor alpha on Lkb1\/Ampk interaction upon adiponectin exposure in breast cancer","volume":"32","author":"Mauro","year":"2018","journal-title":"FASEB J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-262808","article-title":"Estrogen receptor-alpha drives adiponectin effects on cyclin D1 expression in breast cancer cells","volume":"29","author":"Mauro","year":"2015","journal-title":"FASEB J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.007","article-title":"Worldwide burden of, risk factors for, and trends in pancreatic cancer","volume":"160","author":"Huang","year":"2021","journal-title":"Gastroenterology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx012","article-title":"The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: A mendelian randomization study","volume":"109","author":"Carreras-Torres","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26661","article-title":"Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma","volume":"118","author":"Valsecchi","year":"2012","journal-title":"Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1315","article-title":"Insulin-like growth factor-1 receptor expression and disease recurrence and survival in patients with resected pancreatic ductal adenocarcinoma","volume":"29","author":"Du","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030692","article-title":"Fatty pancreas-centered metabolic basis of pancreatic adenocarcinoma: From obesity, diabetes and pancreatitis to oncogenesis","volume":"10","author":"Chang","year":"2022","journal-title":"Biomedicines"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.844028","article-title":"The intricate crosstalk between insulin and pancreatic ductal adenocarcinoma: A review from clinical to molecular","volume":"10","author":"Deng","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2673-2","article-title":"Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer","volume":"58","author":"Tian","year":"2013","journal-title":"Dig Dis Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pharmthera.2016.09.003","article-title":"Kras-related proteins in pancreatic cancer","volume":"168","author":"Mann","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-12-0340-T","article-title":"Kras(G12d)- and Braf(V600e)-induced transformation of murine pancreatic epithelial cells requires Mek\/Erk-stimulated Igf1r signaling","volume":"10","author":"Appleman","year":"2012","journal-title":"Mol Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.27420","article-title":"Adiponectin suppresses human pancreatic cancer growth through attenuating the beta-catenin signaling pathway","volume":"15","author":"Jiang","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13946","article-title":"Leptin-notch signaling axis is involved in pancreatic cancer progression","volume":"8","author":"Harbuzariu","year":"2017","journal-title":"Oncotarget"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1038\/s41598-021-82617-2","article-title":"Obesity reduces the anticancer effect of adiporon against orthotopic pancreatic cancer in diet-induced obese mice","volume":"11","author":"Takenaga","year":"2021","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41419-018-0851-z","article-title":"Antidiabetic adiponectin receptor agonist adiporon suppresses tumour growth of pancreatic cancer by inducing Ripk1\/Erk-dependent necroptosis","volume":"9","author":"Akimoto","year":"2018","journal-title":"Cell Death Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126686","article-title":"Modulation of the leptin receptor mediates tumor growth and migration of pancreatic cancer cells","volume":"10","author":"Mendonsa","year":"2015","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19905","article-title":"Adiponectin receptor agonists inhibit leptin induced Pstat3 and in vivo pancreatic tumor growth","volume":"8","author":"Messaggio","year":"2017","journal-title":"Oncotarget"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.837503","article-title":"Integrating gemcitabine-based therapy with adiporon enhances growth inhibition in human pdac cell lines","volume":"13","author":"Ragone","year":"2022","journal-title":"Front Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.07.025","article-title":"Pre-diagnosis body mass index, physical activity and ovarian cancer mortality","volume":"155","author":"Zamorano","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23497","article-title":"Obesity contributes to the stealth peritoneal dissemination of ovarian cancer: A multi-institutional retrospective cohort study","volume":"30","author":"Iyoshi","year":"2022","journal-title":"Obes (Silver Spring)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e47","article-title":"Obesity-induced peritoneal dissemination of ovarian cancer and dominant recruitment of macrophages in ascites","volume":"18","author":"Ignacio","year":"2018","journal-title":"Immune Netw"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4228","article-title":"Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: An explanation for poor outcomes in obese women","volume":"6","author":"Kato","year":"2015","journal-title":"Oncotarget"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30233","article-title":"The tgfbeta pathway stimulates ovarian cancer cell proliferation by increasing Igf1r levels","volume":"139","author":"Alsina-Sanchis","year":"2016","journal-title":"Int J Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13337","article-title":"Obesity and mortality among endometrial cancer survivors: A systematic review and meta-analysis","volume":"22","author":"Kokts-Porietis","year":"2021","journal-title":"Obes Rev"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-016-0751-4","article-title":"Insulin\/Igf and sex hormone axes in human endometrium and associations with endometrial cancer risk factors","volume":"27","author":"Merritt","year":"2016","journal-title":"Cancer Causes Control"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00349","article-title":"Role of eralpha in mediating female uterine transcriptional responses to Igf1","volume":"158","author":"Hewitt","year":"2017","journal-title":"Endocrinology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"598","DOI":"10.5603\/GP.2016.0052","article-title":"Does igf-1 play a role in the biology of endometrial cancer","volume":"87","author":"Majchrzak-Baczmanska","year":"2016","journal-title":"Ginekol Pol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz202","article-title":"Impact of overweight and obesity on us papillary thyroid cancer incidence trends (1995-2015)","volume":"112","author":"Kitahara","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031116","article-title":"Obesity and thyroid cancer risk: An update","volume":"19","author":"Franchini","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-0743","article-title":"Circulating insulin-like growth factor-1 and risk of total and 19 site-specific cancers: Cohort study analyses from the uk biobank","volume":"29","author":"Qian","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23531","article-title":"Insulin-like growth factor 1 promotes proliferation and invasion of papillary thyroid cancer through the Stat3 pathway","volume":"34","author":"Yang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133258","article-title":"Activation of the igf axis in thyroid cancer: Implications for tumorigenesis and treatment","volume":"20","author":"Manzella","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/srep06855","article-title":"Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to igf-1 receptor, in esophageal carcinoma","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci Rep"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055135","article-title":"Epitope-specific mechanisms of Igf1r inhibition by ganitumab","volume":"8","author":"Calzone","year":"2013","journal-title":"PloS One"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123717","article-title":"Differential effects of igf-1r small molecule tyrosine kinase inhibitors bms-754807 and osi-906 on human cancer cell lines","volume":"12","author":"Fuentes-Baile","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-03-2522","article-title":"Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth","volume":"64","author":"Girnita","year":"2004","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/1535-7163.MCT-13-0598","article-title":"Pharmacodynamic and antineoplastic activity of bi 836845, a fully human igf ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin","volume":"13","author":"Friedbichler","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0588","article-title":"Clinical and translational results of a phase ii, randomized trial of an anti-Igf-1r (Cixutumumab) in women with breast cancer that progressed on endocrine therapy","volume":"22","author":"Gradishar","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.09.008","article-title":"A phase ii study of cixutumumab (Imc-A12, Nsc742460) in advanced hepatocellular carcinoma","volume":"60","author":"Abou-Alfa","year":"2014","journal-title":"J Hepatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the children's oncology group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.06.010","article-title":"An open-label, phase 2 study evaluating the efficacy and safety of the anti-Igf-1r antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours","volume":"49","author":"Schoffski","year":"2013","journal-title":"Eur J Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0670","article-title":"Preliminary efficacy of the anti-Insulin-Like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma","volume":"29","author":"Juergens","year":"2011","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27459","article-title":"A phase 2 study of the insulin-like growth factor-1 receptor inhibitor mk-0646 in patients with metastatic, well-differentiated neuroendocrine tumors","volume":"118","author":"Reidy-Lagunes","year":"2012","journal-title":"Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1253866","article-title":"Phase ii randomized study of the igf-1r pathway modulator Axl1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer","volume":"56","author":"Bergqvist","year":"2017","journal-title":"Acta Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70081-1","article-title":"Linsitinib (Osi-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0574-0","article-title":"A phase 2 study of osi-906 (Linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (Non-opioid requiring) metastatic castrate resistant prostate cancer (Crpc)","volume":"36","author":"Barata","year":"2018","journal-title":"Invest New Drugs"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0774-1","article-title":"Two first-in-Human studies of xentuzumab, a humanised insulin-like growth factor (Igf)-neutralising antibody, in patients with advanced solid tumours","volume":"122","author":"de Bono","year":"2020","journal-title":"Br J Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15231","article-title":"A phase 1 trial of xentuzumab, an igf-neutralizing antibody, in Japanese patients with advanced solid tumors","volume":"113","author":"Doi","year":"2022","journal-title":"Cancer Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040527","article-title":"Identification of a resistance mechanism to igf-ir targeting in human triple negative mda-Mb-231 breast cancer cells","volume":"11","author":"Tsui","year":"2021","journal-title":"Biomolecules"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-018-0922-0","article-title":"Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer","volume":"26","author":"Iida","year":"2019","journal-title":"Breast Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.7150\/jca.69064","article-title":"An insulin growth factor-I\/Ii-Neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth","volume":"13","author":"Ma","year":"2022","journal-title":"J Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32668","article-title":"Igf-1r pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in er-positive breast cancer","volume":"146","author":"Kruger","year":"2020","journal-title":"Int J Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01869-1","article-title":"Igf and mtor pathway expression and in vitro effects of linsitinib and mtor inhibitors in adrenocortical cancer","volume":"64","author":"De Martino","year":"2019","journal-title":"Endocrine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/1078-0432.CCR-14-0940","article-title":"Combination of the mtor inhibitor ridaforolimus and the anti-Igf1r monoclonal antibody dalotuzumab: Preclinical characterization and phase I clinical trial","volume":"21","author":"Di Cosimo","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0115-x","article-title":"Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer","volume":"37","author":"Ireland","year":"2018","journal-title":"Oncogene"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.07.003","article-title":"Systemic analysis of different colorectal cancer cell lines and tcga datasets identified igf-1r\/Egfr-Ppar-Caspase axis as important indicator for radiotherapy sensitivity","volume":"627","author":"Chen","year":"2017","journal-title":"Gene"},{"key":"B112","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/CBM-210016","article-title":"Igf-1r depletion sensitizes colon cancer cell lines to radiotherapy","volume":"32","author":"Zong","year":"2021","journal-title":"Cancer biomark"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1093257\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T06:19:02Z","timestamp":1674454742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1093257\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":112,"alternative-id":["10.3389\/fendo.2023.1093257"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1093257","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"article-number":"1093257"}}